Patrick Daly

DocwireNews

In a randomized controlled trial published in&nbsp;Respiratory Research, researchers compared cysteinyl-leukotriene receptor antagonists (LTRAs) and <a href="https://www.docwirenews.com/latest-pulmonology-news/inhaled-corticosteroids-and-risk-of-obesity-in-asthma/">inhaled corticosteroids</a> plus long-acting &beta;2-agonist (ICS/LABA) using <a href="https://medlineplus.gov/druginfo/meds/a600014.html" target="_blank" rel="noopener">montelukast</a> and budesonide/formoterol, respectively, in patients with cough variant asthma.According to the study&rsquo;s authors, montelukast alone had similar efficacy as budesonide/formoterol alone for reducing cough reflex sensitivity and eosinophilic airway inflammation, and the combination of both treatments yielded additional lung function improvements and alleviated peripheral eosinophils.The study included 99 patients with cough variant asthma who were randomized 1:1:1 to 8 weeks of treatment with montelukast 10 mg once daily, budesonide/formoterol 160/4.5 &mu;g inhaled twice daily, or montelukast plus budesonide/formoterol. The primary end points of the study were cough visual analogue scale (VAS) score, daytime cough symptom score (CSS), and nighttime CSS. Additional end points included cough reflex sensitivity, percentage of sputum eosinophils, and fractional exhaled nitric oxide.<h3>Cough Variant Asthma Treatment With LTRA Versus ICS Plus LABA</h3>The researchers reported that median cough VAS score significantly decreased from:<ul>
<li>6.0 to 2.0 in the montelukast group</li>
<li>5.0 to 1.0 in the budesonide/formoterol group</li>
<li>6.0 to 1.0 in the combination group (P&lt;.01)</li>
</ul>Additionally, daytime CSS and nighttime CSS significantly decreased in all three groups, the authors wrote. Furthermore, cough reflex sensitivity&mdash;defined as the lowest concentration of capsaicin that induced 5 coughs&mdash;and percentage of sputum eosinophils significantly improved for all three groups after 8 weeks (P&lt;.05). Notably, no significant differences were observed among changes in VAS score, daytime and nighttime CSS, cough reflex sensitivity, and percentage of sputum eosinophils from baseline to week 8 between the three groups (P&gt;.05).Patients in the budesonide/formoterol (P=.001) and combination groups (P=.008) also had significant decreases in fractional exhaled nitric oxide, while patients in the montelukast group did not show any significant change (P=.457). The authors noted that the combination regimen also significantly improved forced expiratory volume in 1 second to forced vital capacity ratio, predicted maximal mid-expiratory flow, and percentage of blood eosinophils (P&lt;.05).Overall, the authors suggested that montelukast was comparable with budesonide/formoterol alone and when combined, and that it could be an effective alternative treatment option for patients with cough variant asthma.&rdquo;Whether the combination treatment plays a role in the long-term prognosis of CVA needs to be further investigated,&rdquo; the authors closed.Browse More Recent Asthma Research on the <a href="https://www.docwirenews.com/asthma-resource-center/">DocWire News Resource Center</a>

Jordana Jampel

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Eric Bergson, MD

Rob Dillard

The Role of Multidisciplinary Care in Head and Neck Cancer

Head and Neck Cancer

Sara Nunnery, MD, MSCI

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who’s the Right Patient?

HER2 Breast Cancer

Latest News

Cough Variant Asthma: Montelukast With or Without Budesonide and Formoterol

Asthma

In a randomized controlled trial published in Respiratory Research, researchers compared cysteinyl-leukotriene receptor antagonists (LTRAs) and inhaled corticosteroids plus ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe